Protein prenylation pathway

The **protein prenylation pathway** is a cellular process in which lipid groups—specifically farnesyl or geranylgeranyl isoprenoids—are covalently attached to cysteine residues at the C-terminus of proteins[2][3][4][5][7]. The enzymes involved—farnesyl transferase, geranylgeranyl transferase I (GGTase-I), and geranylgeranyl transferase II (RabGGT)—recognize specific amino acid motifs such as CAAX, CXC, or CC at the protein's C-terminus[2][3][5][7]. Prenylation promotes protein association with cell membranes and is crucial for the function of various signaling proteins, most notably members of the Ras, Rho, and Rab small GTPase families[2][3]. These modified proteins regulate fundamental processes such as cell proliferation, cytoskeletal dynamics, vesicular trafficking, and signal transduction[2][5]. Abnormalities in prenylation are linked to cancer, developmental disorders, and neurodegenerative and cardiovascular diseases[5][6][8]. Therapeutically, the pathway can be targeted by small-molecule inhibitors, particularly in oncology, but challenges include drug specificity and potential impacts on normal cell function[6]. Caveat: "Protein prenylation pathway" refers to a **biochemical pathway/process**, not a discrete molecular target or receptor. It encompasses multiple enzymes, substrates, and cellular processes. Therefore, it is **not classified as a canonical molecular "drug target"** but as a pathway involved in the processing of numerous protein targets. For structured data extraction, focus should be placed on the major enzymes of this pathway (e.g., farnesyl transferase, geranylgeranyl transferase) if a specific molecular target is required.

Other names

Protein isoprenylation pathwayProtein lipidation pathwayPrenylation pathwayIsoprenoid modification pathway

Inhibition of farnesyl transferase (disrupts post-translational farnesylation); Inhibition of geranylgeranyl transferase (prevents geranylgeranylation); Reduction of isoprenoid substrates (e.g., by HMG-CoA reductase inhibition with statins); Blocking membrane localization of small GTPases (e.g., Ras, Rho, and Rab family proteins), thus inhibiting downstream signaling required for cancer cell survival or proliferation.